In advanced liver disease, scientific potency alone is not enough. A therapy must be able to fit real clinical practice, reach the liver selectively, and do so in a way that is workable for patients who may already be fragile and time-limited in their treatment options. Apterna’s approach is being built around that practical requirement: liver-directed activity, limited systemic exposure, and a development path based on an established therapeutic modality rather than an unproven platform.
Built on a Proven Therapeutic Foundation
Apterna’s scientific approach is designed to reduce avoidable platform risk and focus innovation where it matters most. Rather than inventing a new delivery system from scratch, the programme applies a clinically validated RNA therapeutic foundation to a high-value liver problem where existing treatments do not restore the organ function needed to reopen curative pathways.
Making RNA Therapeutics Organ-Specific, Safe, and Scalable
RNA medicine has expanded what is possible in drug discovery, but real-world impact depends on one decisive factor: delivery. Without organ-selective delivery, even the most promising RNA molecules cannot reach the right cells, achieve durable target engagement, or deliver sustained therapeutic benefit.
Apterna’s approach to RNA therapeutics is built around practical translation. The programme is designed for selective liver activity with limited systemic exposure, simple subcutaneous administration, and a manufacturing path that is far less complex than many alternative platforms. By building on an established delivery and regulatory foundation, Apterna can focus its innovation on the biology, the clinical need, and the efficient progression towards scalable real-world use.
Targeting the Epicentre of Metabolic Disease
Why This Profile Matters?
- Targeted liver activity: Designed to concentrate therapeutic effect where the clinical need is greatest while limiting unnecessary systemic exposure.
- Outpatient-friendly use: Built around simple subcutaneous administration rather than hospital-based infusion, making the treatment model easier to integrate into practice.
- Fast enough for the surgical window: Intended for patients whose treatment options depend on improving liver function quickly enough to reopen curative pathways.
Applications:
Initial focus: liver surgery unlock in patients denied curative surgery because liver reserve is too poor.
Next horizon: cirrhosis and transplant avoidance.
Longer-term expansion: fatty liver disease and obesity-related liver dysfunction as clinical evidence builds.
Crossing the Blood–Brain Barrier Without Invasion
The brain is the most protected organ in the body, and that protection has long been one of the greatest barriers to treating CNS disease. Apterna’s brain-targeted platform uses a receptor-guided transport system designed to enable RNA and other macromolecular payloads to cross the blood-brain barrier following simple systemic administration.
Animal Model Results:
- Effective penetration into deep brain tissue following non-invasive systemic administration
- Successful delivery of multiple RNA payload types, including silencing, activating, and coding RNAs
- Modular architecture with potential adaptation across CNS oncology, neurodegenerative, and rare neurological indications
Validated Principles, Modern Engineering
Apterna’s technology builds on proven scientific foundations, enhanced with engineering advances that improve organ selectivity, consistency, and scalable development.
Specificity
Directing the therapeutic only to its target organ
Safety
Minimising off-target effects and systemic exposure
Stability
Engineering RNA constructs for optimal in-vivo persistence
Scalability
Using fully synthetic, non-viral chemistry compatible with global manufacturing standards
Adaptability
Allowing integration with multiple RNA formats
Specificity
Directing the therapeutic only to its target organ
Safety Is the Foundation of Every Apterna Programme
Safety sits at the centre of Apterna’s development philosophy. Every programme is designed and assessed through rigorous non-clinical evaluation, focusing on organ-selective biodistribution, immune tolerability, and longer-term safety in the target tissue.
- Advanced biodistribution profiling supported by state-of-the-art molecular imaging and quantitative tissue analytics
- GLP toxicology studies delivered with certified partners and regulatory-grade documentation
- Regulatory alignment with international standards and expectations, including ICH, GCP, and GMP pathways
- Early safety and pharmacovigilance planning to support robust monitoring from first-in-human studies onward
Discovery
Preclinical Safety
GLP Validation
Regulatory Readiness
First-in-Human
From Discovery to Clinical Proof-of-Concept
Apterna’s development roadmap is designed to de-risk progress at every stage. Each platform advances through clear, evidence-led steps, from molecular design and preclinical validation to regulatory readiness and clinical execution.
1
Target Discovery
Selection based on strong mechanistic rationale and unmet clinical need
2
Molecular Design
Optimisation of RNA constructs for potency, stability, and manufacturability
3
In-Vivo Validation
Testing for organ-specific delivery, biodistribution, and safety
4
Regulatory Preparation
Assembly of preclinical and CMC packages under ICH-compliant standards
5
Clinical Translation
Initiation of early-phase studies in defined high-need populations
Empowering the Broader RNA Ecosystem
While Apterna’s internal focus is on liver and brain indications, our delivery technologies are modular and partner-ready. We welcome collaboration with pharmaceutical, academic, and biotechnology teams seeking organ-targeted delivery for new RNA or nucleic acid programmes.
Platform Licensing
Platform Licensing for CNS or liver and metabolic applications
Co-development Agreements
Co-development for novel RNA payloads, combinations, or lifecycle extensions
Joint Research Ventures
Joint Research Ventures with universities and translational centres
Precision Delivery Is the Future of RNA Medicine — and It Starts Here
At Apterna, we believe RNA therapeutics should be as precise as they are powerful. Our dual-platform approach is designed to enable organ-targeted treatments that act at the source of disease while maintaining a strong focus on safety, manufacturability, and real-world clinical relevance.
We are preclinical, but we are building with intent: rigorous science, validated delivery principles, and a partnership-minded development model designed to support long-term therapeutic and commercial value.